Carrington Laboratories Inc. issues third quarter results.Laboratories, Inc., (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CARN) today announced results of operations for the quarter ended Sept. 30, 1995. Revenues were $6,621,000 and net income was $162,000 or $.01 per share compared with revenues of $6,252,000 and net income of $446,000 for the same period during the previous year. Total sales grew by 6 percent over the same period last year. Year to date, through the third quarter, Carrington Carrington or Carington is a surname, and may refer to:
Carlton Carl·ton , Steven Norman Known as "Steve." Born 1944. American baseball player. As a left-handed pitcher with the Philadelphia Phillies (1972-1985), he became the first pitcher to win four Cy Young Awards (1972, 1977, 1980, and 1982). E. Turner, president & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. said, "The third quarter of the year was a period of solid progress for the company. We signed an agreement with a clinical research organization (CRO) to manage our Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the of CARN 1000 oral capsules for the treatment of ulcerative colitis This article concerns the treatment of ulcerative colitis, a form of inflammatory bowel disease (IBD). Ulcerative colitis is a form of colitis, a disease of the intestine, specifically the large intestine or colon, that includes characteristic ulcers, or open sores, in the colon. . Patient enrollment began in September. We anticipate that the 35 sites involved in this study will provide sufficient patients to complete treatment trials next year." Although unit sales unit sales Sales measured in terms of physical units rather than dollars. Unit sales data are often used by financial analysts when evaluating the health of a company. were up more than 9 percent over the same period last year, sales volumes in the wound and sales division were impacted by downward price adjustments. Currently, the company's products compete in a $28 million mature hydrogel hy·dro·gel n. A colloidal gel in which the particles are dispersed in water. hydrogel a gel that contains water. hydrogel Wound care A polymer absorptive wound dressing. See Dressing. wound care market. Carrington has developed or acquired new products which will enable it to compete in four additional wound care markets with estimated sales potential in excess of $250 million. The bulk of these new products will be launched during the first quarter of 1996. Carrington Laboratories, Inc., is an emerging research-based pharmaceutical and medical device company engaged in developing complex carbohydrate-based therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. and in manufacturing and marketing products for the management of wounds. -0-
For the Quarter Ended September 30
----------------------------------
1995 1994
----------- -----------
Net Sales $ 6,621,395 $ 6,251,750
Net Income 161,904 445,848 Net Income per Share .01 .06
For the Nine Months Ended September 30
--------------------------------------
1995 1994
----------- -----------
Net Sales $19,305,035 $18,467,520
Net Income (621,439) 1,040,848 Net Income per Share (.09) .13 -0- CONTACT: Carrington Laboratories Inc. Jim Blackmore, 214/988-3736 Chris Record, 214/518-1300 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion